摘要
目的系统评价α-干扰素联合拉米夫定与单独应用α-干扰素治疗儿童乙肝患者的疗效及安全性。方法计算机检索e Cochrane Library(2012年第4期)、PubMed、EMbase、Web of Science、CBM、CNKI、VIP和WanFang Data,检索时限均为从建库至2012年12月,并辅以手工检索,收集α-干扰素联合拉米夫定治疗儿童乙肝的随机对照试验(RCT)。由两位研究者按照纳入和排除标准独立筛选试验、提取资料和评价方法学质量后,采用RevMan 5.0软件进行Meta分析。结果共纳入8个RCT,各研究间基线均可比。Meta分析结果显示:与单用α-干扰素相比,α-干扰素联合拉米夫定组儿童乙肝患儿血清HBV-DNA阴转率[OR=4.17,95%CI(2.22,7.83),P<0.000 01]和HBeAg阴转率[OR=5.22,95%CI(2.64,10.29),P<0.000 01]均明显提高。而在血清抗-HBe阳转率、不良反应方面,两组差异无统计学意义。结论当前证据显示,儿童乙肝患者应用α-干扰素联合拉米夫定的治疗方案优于单用α-干扰素治疗。
Objective To systematically review the effectiveness and safety interferon-α（IFN-α） combined with lamivudine vs.IFN-α alone in treating children with Hepatitis B.Methods Such databases as The Cochrane Library,PubMed,EMbase,Web of Science,CBM,CNKI,VIP and WanFang Data were electronically searched for randomized controlled trials（RCTs） on IFN-α combined with lamivudine in treating children with hepatitis B.Two reviewers screened literature,extracted data,and assessed the methodological quality of the included studies.Then,meta-analysis was performed using RevMan 5.0 software.Results 8 RCTs were included,with comparable baseline.The results of meta-analysis showed that,compared to the IFN-α alone group,the combined therapy group had higher negative rates of serum HBV-DNA and HBeAg.There was no significant difference in the positive rate of anti-Hbe and the incidence of adverse reaction between the two groups.Conclusion Current evidence shows that IFN-α combined with lamivudine was more effective than IFN-α alone in treating children＇s hepatitis B.
出处
《中国循证医学杂志》
CSCD
2013年第8期1013-1017,共5页
Chinese Journal of Evidence-based Medicine
